Acaster Lloyd Consulting Ltd, London, UK.
Kyowa Kirin International PLC, Marlow, UK.
J Med Econ. 2020 Oct;23(10):1142-1150. doi: 10.1080/13696998.2020.1793764. Epub 2020 Jul 25.
Cutaneous T-cell Lymphoma (CTCL) is a rare form of non-Hodgkin lymphoma characterized by skin lesions, which can negatively impact the quality of life of both patients and their caregivers. The Decision Support Unit (DSU) at the National Institute for Health and Care Excellence (NICE) in the UK recently outlined a rationale for the inclusion of caregiver burden in economic evaluations. This study aimed to estimate utilities for health states associated with being a caregiver for an individual with CTCL at different stages of treatment.
A targeted literature review and interviews with CTCL specialists informed the development of health state vignettes describing the experience caring for an individual with CTCL. The vignettes were evaluated in interviews with the UK general population using a visual analogue scale (VAS), the time trade-off (TTO) method and the EQ-5D-5L.
Four vignettes were developed describing the caregiver experience for an individual with CTCL on i) second line treatment, ii) third line treatment, iii) end of life care, iv) a post-patient death. One hundred interviews were conducted to evaluate the health state vignettes. The pattern of results was similar across the evaluation methods: second line treatment (VAS: 39.2, TTO = 0.52, EQ-5D-5L: 0.56), third line treatment (VAS: 31.1, TTO = 0.39, EQ-5D-5L: 0.37), end of life care (VAS: 28.2, TTO = 0.37, EQ-5D-5L: 0.31) and post-patient death (VAS: 41.2, TTO = 0.63, EQ-5D-5L: 0.59). These findings highlight the substantial burden of caring for an individual with CTCL and the importance of including caregiver burden in the health technology assessment review process. A limitation is the hypothetical vignette approach, which meant the TTO participants did not have experience of caring for individuals with CTCL, but were imagining this state. There is also the possibility that they may also be considering the patient experience when responding to the questions.
皮肤 T 细胞淋巴瘤(CTCL)是一种罕见的非霍奇金淋巴瘤,其特征是皮肤损伤,这会对患者及其护理人员的生活质量产生负面影响。英国国家卫生与保健优化研究所(NICE)的决策支持部门(DSU)最近概述了将护理人员负担纳入经济评估的基本原理。本研究旨在估计与 CTCL 患者在不同治疗阶段的护理人员相关的健康状况效用。
有针对性的文献回顾和与 CTCL 专家的访谈为描述护理 CTCL 患者的经验的健康状况描述符的开发提供了信息。使用视觉模拟量表(VAS)、时间权衡(TTO)方法和 EQ-5D-5L 对 vignettes 进行了来自英国普通人群的访谈评估。
开发了四个 vignettes,描述了处于以下阶段的 CTCL 患者的护理人员体验:i)二线治疗、ii)三线治疗、iii)临终关怀、iv)患者死亡后。进行了 100 次访谈以评估健康状况描述符。评估方法的结果模式相似:二线治疗(VAS:39.2,TTO = 0.52,EQ-5D-5L:0.56)、三线治疗(VAS:31.1,TTO = 0.39,EQ-5D-5L:0.37)、临终关怀(VAS:28.2,TTO = 0.37,EQ-5D-5L:0.31)和患者死亡后(VAS:41.2,TTO = 0.63,EQ-5D-5L:0.59)。这些发现强调了照顾 CTCL 患者的巨大负担,以及在健康技术评估审查过程中纳入护理人员负担的重要性。一个限制是假设的 vignette 方法,这意味着 TTO 参与者没有照顾 CTCL 患者的经验,但想象这种状态。他们在回答问题时也可能考虑到患者的体验。